SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“CNS”) disorders, today announced the pricing of a $100 million underwritten offering of its common stock (or pre-funded warrants to purchase common stock) and warrants to purchase common stock (or pre-funded warrants in lieu thereof), before deducting underwriting discounts and commissions and estimated offering expenses..

南旧金山，加利福尼亚州-（商业线）-Vistagen Therapeutics，Inc.（“Vistagen”）（纳斯达克：VTGN），一家晚期临床阶段的生物制药公司，旨在改变焦虑，抑郁和其他中枢神经系统（“CNS”）疾病，今天宣布定价1亿美元承保提供其普通股（或购买普通股的预先资助的认股权证）和购买普通股（或代替其的预先资助的认股权证），然后扣除承保折扣和佣金，估计提供费用。。

The financing was led by BVF Partners LP with participation from Commodore Capital, Great Point Partners, Logos Capital, Nantahala Capital, Surveyor Capital (a Citadel company), and TCGX along with additional institutional investors.

该融资由BVF Partners LP领导，Commodore Capital，Great Point Partners，Logos Capital，Nantahala Capital，Surveyor Capital（一家城堡公司）和TCGX以及其他机构投资者参与。

At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen common stock, accompanying warrants to purchase up to 9,294,022 shares of Vistagen common stock (or pre-funded warrants in lieu thereof) at an exercise price of $5.38 per share or pre-funded warrant (the “T1 Warrants”), and accompanying warrants to purchase up to 11,265,086 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $8.877 per share or pre-funded warrant (the “T2 Warrants”); and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,577,240 shares of Vistagen common stock, accompanying T1 Warrants and accompanying T2 Warrants at a combined price of $5.379 per pre-funded warrant, accompanying T1 Warrant and accompanying T2 Warrant, which represents the per share offering price for the common stock, accompanying T1 Warrant and accompanying T2 Warrant less the $0.001 per share exercise price for each such pre-funded warrant, in each case before deducting underwriting discounts and commissions.

以普通股，随附T1认股权证及随附T2认股权证（定义见下文）的5.38美元的综合购买价格，本次发行包括15010810股Vistagen普通股，随附认股权证以行使价5.38美元/股或预先发行认股权证（“T1认股权证”）购买多达9294022股Vistagen普通股股份（或代替其的预先资助认股权证），及随附认股权证，以行使价8.877元/股或预先资助认股权证（“T2认股权证”）购买多达11265086股普通股股份（或代替其预先资助认股权证）；并且，对于某些代替普通股的投资者，预先资助的认股权证以每个预先资助的认股权证，随附的T1认股权证及随附的T2认股权证的总价格5.379美元购买多达3577240股Vistagen普通股，随附的T1认股权证及随附的T2认股权证，代表普通股的股份发行价格，伴随的T1认股权证及随附的T2认股权证在扣除承保折扣及佣金之前，均须为每项此类预先资助认股权证减价0.001美元。

Each share of common stock or pre-funded warrant will be sold with an accompanying T1 Warrant and T2 Warrant..

普通股或预先资助认股权证的每股股份将连同随附的T1认股权证及T2认股权证一起出售。。

The total gross proceeds to Vistagen from this offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Vistagen and excluding any potential future proceeds of up to $50 million from the exercise of the T1 Warrants and up to $100 million from the exercise of the T2 Warrants.

在扣除由Vistagen应付的承保折扣和佣金以及估计的发行费用之前，本次发行的Vistagen所得款项总额预计约为1亿美元，并且不包括行使T1认股权证未来可能获得的高达5000万美元的任何所得款项，从行使T2认股权证中最多可获得1亿美元。

Vistagen intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, for research, development, manufacturing, and regulatory expenses associated with development of its product candidates, including, primarily, its PALISADE Phase 3 program for fasedienol for the acute treatment of anxiety in adults with social anxiety disorder ('SAD'), and for other working capital and general corporate purposes.

Vistagen打算将提供的净收益及其现有现金和现金等价物用于与其候选产品开发相关的研究，开发，制造和监管费用，主要包括其针对fasedienol的栅栏第3阶段计划社交焦虑症（'SAD'）成人焦虑症的急性治疗，以及其他营运资本和一般公司用途。

If its PALISADE Phase 3 program is successful, Vistagen believes the proceeds from this offering, together with its existing cash and cash equivalents, will be sufficient to fund its operations through its potential submission of a U.S. New Drug Application for fasedienol for the acute treatment of anxiety in adults with SAD.

如果其栅栏第3阶段计划成功，Vistagen认为此项产品的收益及其现有的现金和现金等价物将足以通过其可能提交美国新药申请fasedienol来急性治疗成人焦虑症，从而为其运营提供资金。

All of the shares of common stock, pre-funded warrants, T1 Warrants, and T2 Warrants to be sold in the offering are being sold by Vistagen. The offering is expected to close on October 4, 2023, subject to the satisfaction of customary closing conditions..

在该产品中出售的普通股，预先资助的认股权证，T1认股权证和T2认股权证的所有股份均由Vistagen出售。在满足习惯性结算条件的前提下，预计该产品将于2023年10月4日结束。。

Jefferies, Stifel, and William Blair are acting as joint book-running managers for the offering.

Jefferies，Stifel和William Blair正担任该产品的联合图书运营经理。

These securities were offered by Vistagen pursuant to its existing shelf registration statement (File No. 333-254299) filed with the Securities and Exchange Commission (“SEC”) on March 15, 2021 and declared effective on March 26, 2021. A prospectus supplement describing the terms of the offering will be filed with the SEC and will form a part of the effective registration statement.

这些证券由Vistagen根据其于2021年3月15日提交给证券交易委员会（“SEC”）的现有货架注册声明（文件号333-254299）提供，并于2021年3月26日宣布生效。描述发行条款的IPO补充资料将与证券交易委员会一起提交，并将成为有效注册声明的一部分。

When available, copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340, or by email at Prospectus_Department@Jefferies.com; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com.

如果有的话，可以通过联系Jefferies LLC，注意：股权集团承销说明书部门，520 Madison Avenue，2nd Floor，New York，NY 10022，通过电话（877）547-6340，或通过电子邮件Prospectus_Department@Jefferies.com; Stifel，Nicolaus＆Company，Incorporated，Attention:Syndue，One Montgomery Street，Suite 3700，San Francisco，CA 94104，电话（415）364-2720，或通过电子邮件syndprospectus@stifel.com; 或William Blair＆Company，L.L.C.，注意：IPO部门，150 North Riverside Plaza，Chicago，IL 60606，通过电话（800）621-0687，或通过电子邮件prospectus@williamblair.com.

An electronic copy of the prospectus supplement and accompanying prospectus relating to the offering will be available on the SEC website at www.sec.gov..

与该产品有关的IPO补充说明和随附的IPO的电子副本将在SEC网站www.SEC.gov上提供。。

This press release does not constitute an offer to sell or the solicitation of offers to buy any securities of Vistagen, and shall not constitute an offer, solicitation, or sale of any security in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售或征求购买Vistagen任何证券的报价，也不构成在任何州或管辖区内任何证券的报价，征求或销售，在根据任何此类州或管辖区的证券法注册或鉴定之前，销售将是非法的。。

About Vistagen

关于Vistagen

Vistagen is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression, and multiple CNS disorders.

Vistagen是一家晚期临床阶段的生物制药公司，旨在改变患有焦虑，抑郁和其他中枢神经系统疾病的个体的治疗环境。Vistagen正在推进治疗方法，与目前可用于治疗焦虑症，抑郁症和多种中枢神经系统疾病的药物相比，具有更快的疗效，更少的副作用和安全性问题。

Vistagen’s pipeline includes six clinical-stage product candidates, including fasedienol, itruvone, PH80, PH15, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral prodrug of an antagonist of the N-methyl-D-aspartate receptor.

Vistagen的管道包括六种临床阶段候选产品，包括法舒地诺，伊曲酮酮，PH80，PH15和PH284，每种都是属于一类新药物的研究药物，称为pherines，以及AV-101，它是一种口服前药。N-甲基-D-天冬氨酸受体拮抗剂。

Pherines are neuroactive nasal sprays designed with an innovative proposed mechanism of action that activates chemosensory neurons in the nasal cavity and can beneficially impact key neural circuits in the brain without systemic absorption or direct activity on neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression, and several other CNS disorders..

Pherines是神经活性鼻腔喷雾剂，其设计具有创新的提出的作用机制，其激活鼻腔中的化学感应神经元，并且可以有益地影响大脑中的关键神经回路，而没有全身吸收或直接活动大脑中的神经元。Vistagen致力于改变精神卫生保健并重新定义治疗焦虑，抑郁和其他几种中枢神经系统疾病的可能性。。

Forward-looking Statements

前瞻性声明

Certain of the statements made in this press release are forward-looking, such as those, among others, relating to Vistagen’s expectations regarding the completion of the offering, including the anticipated use of proceeds therefrom. Actual results or developments may differ materially from those projected or implied in these forward-looking statements.

本新闻稿中所作的某些陈述是前瞻性的，例如与Vistagen对完成提供的期望有关的声明，包括预期使用其收益。实际结果或发展可能与这些前瞻性声明中预测或暗示的结果或发展有很大不同。

Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not Vistagen will be able to raise capital through the sale of shares of common stock, pre-funded warrants, T1 Warrants, and T2 Warrants; the final terms of the offering, market, and other conditions; the satisfaction of customary closing conditions related to the offering; and the general economic, industry, or political conditions in the United States or internationally.

可能导致这种差异的因素包括但不限于与Vistagen是否能够通过出售普通股股份，预先资助的认股权证，T1认股权证和T2认股权证筹集资本有关的风险和不确定性；产品的最终条款，市场和其他条件；满足与提供相关的习惯性关闭条件；以及美国或国际上的一般经济，工业或政治条件。

There can be no assurance that Vistagen will be able to complete the offering on the anticipated terms, or at all. Vistagen will need to raise additional capital to fund its operations and may be unable to raise capital when needed, which would force Vistagen to delay, reduce, or eliminate its product development programs and/or commercialization efforts.

无法保证Vistagen能够按照预期条款或根本完成提供。Vistagen将需要筹集额外资金来资助其运营，并且在需要时可能无法筹集资金，这将迫使Vistagen推迟，减少或消除其产品开发计划和/或商业化工作。

You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Other risks and uncertainties include, but are not limited to, issues related to: adverse healthcare reforms and changes of laws and regulations; manufacturing and marketing risks; inadequate and/or untimely supply of one or more of Vistagen’s drug candidates to meet demand; entry of competitive products; and other technical and unexpected hurdles in the development, manufacture, and commercialization of its drug candidates, as well as those risks more fully dis.

您不应过分依赖这些前瞻性声明，这些声明仅适用于本新闻稿发布之日。其他风险和不确定性包括但不限于以下问题：不利的医疗改革和法律法规的变化；制造和营销风险；一种或多种Vistagen候选药物供应不足和/或不合时宜以满足需求；竞争产品的进入；以及候选药物开发，制造和商业化方面的其他技术和意外障碍，以及更充分的风险。